Skip to main content
. 2021 Mar 19;13(6):1394. doi: 10.3390/cancers13061394

Figure 6.

Figure 6

Therapy of experimental pancreatic adenocarcinoma using armed MYXV construct. C57Bl/6NCrl mice (n = 10–11) with induced orthotopic lesions were injected IP (days 4, 8, 12, 16 and 20) with LIGHT-expressing vMyx-mLIGHT-Fluc/tdTr, either ADSC-shielded or unshielded, or with PBS−; (a) timeline of experiment; (b) size of pancreata, 21st day; (c) weight of pancreata and spleen, 21st day; (d–f) flow cytometry data showing CD4+ and CD8+ cell percentages among CD3+ lymphocytes in the blood and pancreas; (g) histological appearance of representative H&E-stained sections (scale bars: 50 µm, magn. 48×): lymphocytic infiltrates: yellow ellipses, (h) mitotic index rated under 400× magnification for 10 high power fields (HPF); (i) mouse survival (n = 7–8): log-rank (Mantel–Cox) test; p = 0.0015. The data (mean ± SD) were analyzed with one-way ANOVA; statistically significant differences are indicated (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; ns – not significant).